Virtual Screening in Drug Design and Development

被引：0

作者：

Sousa, Sergio F. ^{[1
]}

Cerqueira, Nuno M. F. S. A. ^{[1
]}

Fernandes, Pedro A. ^{[1
]}

Ramos, Maria Joao ^{[1
]}

机构：

[1] Univ Porto, REQUIMTE, Dept Quim, Fac Ciencias, P-4169007 Oporto, Portugal

来源：

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING | 2010年 / 13卷 / 05期

关键词：

Drug design; docking; scoring; filters; compound libraries; druggability; protein flexibility; computational chemistry; PROTEIN-COUPLED RECEPTORS; MOLECULAR DOCKING; CHEMICAL DATABASES; LEAD OPTIMIZATION; LIGAND DOCKING; DISCOVERY; FLEXIBILITY; STRATEGIES; INHIBITORS; BETA;

D O I：

暂无

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Virtual screening (VS) is presently a key component in the process of drug design and development. VS is normally regarded as the selection of likely drug candidates from large libraries of chemical structures by using computational methodologies. However, the generic definition of VS is significantly wider and may encompass many different methods. This review tries to present a comprehensive overview of the virtual screening process and of its importance in the present drug discovery and development paradigm. Following a focused contextualization on the subject, an introduction to the general types of virtual screening methodologies is presented. The main stages of a virtual screening campaign, including its strengths and limitations, are the subject of particular attention in this review. This analysis is complemented with a careful selection of VS success stories. Finally, a reflection on the future challenges of this promising methodology is drawn.

引用

下载

页码：442 / 453

页数：12

共 50 条

[41] Virtual screening of chemical libraries for drug discovery
Green, Darren V. S.
EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (09) : 1011 - 1026
[42] STRATEGIES IN ANTIEPILEPTIC DRUG DEVELOPMENT - IS RATIONAL DRUG DESIGN SUPERIOR TO RANDOM SCREENING AND STRUCTURAL VARIATION
LOSCHER, W
SCHMIDT, D
EPILEPSY RESEARCH, 1994, 17 (02) : 95 - 134
[43] High-throughput screening, virtual screening and rational drug design identify potent inhibitors for Pseudomonas aeruginosa RmlA
Sarkar, Aurijit
Gardiner, Mary
Alphey, Magnus S.
Gray, David
Naismith, James
Brenk, Ruth
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[44] A STATISTICAL DESIGN FOR DRUG SCREENING
KING, EP
BIOMETRICS, 1963, 19 (03) : 429 - &
[45] Molecular modeling of drug-DNA interactions: Virtual screening to structure-based design
Ma, Dik-Lung
Chan, Daniel Shiu-Hin
Lee, Paul
Kwan, Maria Hiu-Tung
Leung, Chung-Hang
BIOCHIMIE, 2011, 93 (08) : 1252 - 1266
[46] Computer especially AI-assisted drug virtual screening and design in traditional Chinese medicine
Lin, Yumeng
Zhang, You
Wang, Dongyang
Yang, Bowen
Shen, Ying-Qiang
PHYTOMEDICINE, 2022, 107
[47] Using machine learning method for drug design to develop a high-performance virtual screening
Okada, Masato
Kanamori, Katsutoshi
Aoki, Shin
Ohwada, Hayato
Transactions of the Japanese Society for Artificial Intelligence, 2014, 29 (01) : 194 - 200
[48] Machine learning for hit discovery: Recent work in virtual screening and de novo drug design
Amaro, Rommie
Parks, Conor
Gaieb, Zied
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
[49] Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening
Yusuf Tanrikulu
Gisbert Schneider
Nature Reviews Drug Discovery, 2008, 7 : 667 - 677
[50] Combining ligand-based and structure-based drug design in the virtual screening arena
Moro, Stefano
Bacilieri, Magdalena
Deflorian, Francesca
EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (01) : 37 - 49

← 1 2 3 4 5 →